The rebiopsy of the sacroiliac bone (right side) performed on 30 August 2024 indicated TTF-1(3+), PDL1(22C3) (TPS:3%), and PDL1(22C3Neg) (−), and the molecular screening of sacroiliac bone biopsy tumor tissue by a large gene new-generation sequencing (NGS) panel analysis identified EGFR 19 exon p.L747-P753 mutation (38.6%), TP53 exon8 p.V272L mutation (40.7%), CD8 exon2 p.A50D (13.5%), WPN exon33 p.A1297G (2.3%), IL7R exon3 p.N106I mutation (14.6%), and CCNE1 (CN=3.9) amplification. Here, EGFR is linked to neoplasm.